Invivyd (IVVD) Other Non-Current Liabilities (2021 - 2023)
Invivyd posted quarterly Other Non-Current Liabilities of $700000.0 for Q4 2023, little changed on a QoQ basis from $700000.0 in Q3 2023.
Invivyd (IVVD) has 2 years of Other Non-Current Liabilities data on file, last reported at $700000.0 in Q4 2023.
- For the quarter ending Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $700000.0; the trailing twelve-month figure through Dec 2023 stood at $700000.0 (changed N/A YoY), and the FY2023 full-year result was $700000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2023 stood at $700000.0, roughly flat from $700000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $700000.0 in Q3 2023 and bottomed at $6000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 700,000.00 |
| Dec 31, 2021 | 6,000.00 |